The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Sales Down by 7.8% due to Slump of Long-Listed Drugs, Transfer of Marketing Rights for Cabaser: Kissei
November 8, 2012
- Nippon Shinyaku Confident about Achieving Target in Mid-Term Management Plan Backed by Steady Growth of New Products
November 8, 2012
- Ono: New Products Grow in 1st Half, Glactiv to Become Top-Selling Product
November 8, 2012
- Alfresa HD “Reached Some Degree of Agreement with Customers” Despite Non-Agreement Rate of Over 60% in 1st Half: President Ishiguro
November 8, 2012
- Kyorin Drops Development of DPP-4 Inhibitor as It Fails to Find Partner
November 8, 2012
- Otsuka Forms JV with Turkey’s No. 1 Drug Maker, Set to Launch Samsca in 2013
November 7, 2012
- Tolvaptan Suppresses Rate of Increase in Total Kidney Volume by 50%: Otsuka
November 7, 2012
- Eli Lilly Japan, Chugai to Terminate Comarketing Agreement for Evista
November 7, 2012
- Takeda to Buy Envoy of US to Reinforce Drug Discovery Prowess
November 7, 2012
- Ono Achieves Target Reduction of Sales Ratio of Long-Listed Drugs to Mid-50% Level: President Sagara
November 7, 2012
- Generic Sales Ratio Exceeds 80% for First Time in Interim Results: Nippon Chemiphar
November 6, 2012
- Abbott Splits into Two Companies; Research-Based Pharmaceuticals, Diversified Medical Products
November 6, 2012
- Abbott Japan Spins Off New Drug Biz, Establishes New Firm “AbbVie”
November 6, 2012
- Sawai’s Status Improved Within Mediceo by Utilizing ARs
November 6, 2012
- Asahi Kasei Pharma 1st Half Sales Show Significant Growth, Teribone May Exceed Peak Sales in 1st Year
November 6, 2012
- Astellas Logs Sales of 25.5 Bil. Yen in Oncology Sector, Investments Bearing Fruit: Pres. Hatanaka
November 5, 2012
- Shionogi Enjoys Sales, Profit Growth in 1st Half, 8 Strategic Products Make Up 50% of Japan Sales
November 5, 2012
- Domestic Drug Makers’ Major Products See Sharp Declines in 1st Half; Sales of Aricept, Lipitor Down 30%
November 5, 2012
- Eisai to Go on Offensive for Aricept by Introducing Consultation Date Reminder Service for Patients: President Naito
November 5, 2012
- Astellas Discontinues Development of SGLT-2 Inhibitor Ipragliflozin in Europe, US; Development in Japan to Go Forward
November 5, 2012
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…